I-01 Jeroen Elassaiss-Schaap Translational Pharmacokinetic/Pharmacodynamic Model of Tumor Growth Inhibition by the New Anti-PD1 Monoclonal Antibody MK-3475 Wednesday 10:20-11:50 |
I-02 Moran Elishmereni Improved sunitinib therapy in non-small cell lung cancer as predicted by a new mixed-effects model Wednesday 10:20-11:50 |
I-06 Sylvain Fouliard Cardiac safety monitoring in early oncology trials using optimal design and M&S approach Wednesday 10:20-11:50 |
I-10 María García-Cremades Pharmacokinetic and Pharmacodynamic analysis of Gemcitabine in pancreatic cancer in mice. Wednesday 10:20-11:50 |
I-14 Ekaterina Gibiansky Population Pharmacokinetics of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL) Wednesday 10:20-11:50 |
I-29 Stefanie Hennig Population pharmacokinetics of high dose methotrexate in non-Hodgkin lymphoma patients Wednesday 10:20-11:50 |
I-32 Mistry Hitesh Virtual Tumour Clinical: translational modelling of vemurafenib, selumetinib and docetaxel inmetastatic melanoma Wednesday 10:20-11:50 |
I-37 Bart Jacobs Model based optimization of a novel controlled release formulation of capecitabine Wednesday 10:20-11:50 |
I-41 Jin Jin Longitudinal Safety Modeling and Simulation for Regimen Optimization of Vismodegib in Operable Basal Cell Carcinoma Wednesday 10:20-11:50 |
II-19 Victor Mangas-Sanjuan Semi-mechanistic cell cycle PKPD model of chemotherapy-induced neutropenia Wednesday 15:10-16:30 |
II-34 Ida Neldemo Predicting the absolute neutrophil count with frequent measurements during docetaxel-induced myelosuppression Wednesday 15:10-16:30 |
II-35 Yookhwan Noh Population pharmacokinetics of HM781-36 and its metabolites in patients with advanced solid tumors Wednesday 15:10-16:30 |
II-41 Aziz Ouerdani Tumor growth and angiogenesis inhibition modeling: Effects of pazopanib on preclinical and clinical tumor size data Wednesday 15:10-16:30 |
II-42 Katie Owens Population K-PD modelling of lymph node size in lymphoma patients treated with abexinostat, a histone deacetylase inhibitor (HDACi). Wednesday 15:10-16:30 |
II-43 Eirini Panoilia A population PK model for bevacizumab when combined with chemotherapy in patients with metastatic colorectal cancer stage IV Wednesday 15:10-16:30 |
II-45 Zinnia Parra-Guillen Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer Wednesday 15:10-16:30 |
II-48 Jonás Samuel Pérez-Blanco Population pharmacokinetic of doxorubicin and doxorubicinol in hematological patients Wednesday 15:10-16:30 |
II-55 Benjamin Ribba On the use of model-based tumor size metrics to predict survival Wednesday 15:10-16:30 |
III-21 Dean Bottino Operating Characteristics of Tumor Kinetic Response Assessments in Early Phase Oncology Trials Thursday 10:05-11:30 |
III-24 Frances Brightman Predicting clinical response using preclinical data: translational modelling of docetaxel-thalidomide combination treatment in metastatic, castrate-resistant, prostate cancer Thursday 10:05-11:30 |
III-26 Claire Brillac Population PK/PD modeling of tumor growth inhibition in tumor bearing mice: a translational strategy to predict clinical efficacy ? Thursday 10:05-11:30 |
III-27 René Bruno Exposure-Response Modeling and Simulation of lucitanib Induced Dose Limiting Toxicities and Response Categories in Patients with Solid Tumors Thursday 10:05-11:30 |
III-31 Juan Pablo Cayun Pellizaris Association between genetic, adverse events and pharmacokinetics in testicular cancer patients. Thursday 10:05-11:30 |
III-32 Pascal Chanu Population pharmacokinetic/pharmacodynamic models to support dose selection of daratumumab in multiple myeloma patients Thursday 10:05-11:30 |
III-43 Pieter Colin A model-based analysis of IPEC dosing of paclitaxel in rats. Thursday 10:05-11:30 |
III-46 Ana Margarita Contreras Sandoval PK/PD modeling of new immunotherapeutic agents in cancer Thursday 10:05-11:30 |
III-48 Damien Cronier A semi-mechanistic PK/PD model of vemurafenib resistance and its rescue by LY2835219, a cyclin-dependent kinase 4/6 inhibitor, in mice bearing human melanoma xenograft tumours Thursday 10:05-11:30 |
III-49 Chantal Csajka Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients Thursday 10:05-11:30 |
III-53 Kristin Dickschen Application of Physiologically-Based Pharmacokinetic/Pharmacodynamic Modelling in Oncology Thursday 10:05-11:30 |
IV-01 Stefaan Rossenu Population Pharmacokinetics of MK-3475, a human Anti-PD-1 Monoclonal Antibody in patients with progressive locally advanced or metastatic carcinoma, melanoma, and non-small cell lung carcinoma Thursday 15:15-16:40 |
IV-03 Maria Luisa Sardu Steady-state equivalence of drug- and biomarker driven models in tumor growth experiments Thursday 15:15-16:40 |
IV-05 Emilie Schindler PKPD-Modeling of individual lesion maximal standardized uptake value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib Thursday 15:15-16:40 |
IV-10 Kwang-Hee Shin A population pharmacokinetic/pharmacodynamic approaches of a peglyated granulocyte-colony stimulating factor (G-CSF) in healthy Korean Thursday 15:15-16:40 |
IV-19 Mark Stroh Meta-analysis of Published Efficacy and Safety Data for Docetaxel in Second-Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer Thursday 15:15-16:40 |
IV-21 Kim Stuyckens Modelling and simulation approach to optimize the pharmacological activity during a Phase 1 study of JNJ-42756493, a selective and potent FGFR 1, 2 ,3 and 4 inhibitor. Thursday 15:15-16:40 |
IV-22 Siddharth Sukumaran Development of a Mechanism-based pharmacokinetic model for MMAE conjugated ADCs Thursday 15:15-16:40 |
IV-23 Ahmed Suleiman A survival modeling analysis evaluating the use of positron emission tomography with [(18)F]-fluorodeoxyglucose for predicting the prognosis in advanced non-small cell lung cancer patients first-treated with erlotinib Thursday 15:15-16:40 |
IV-26 Nadia Terranova An energy based model able to describe the effect of anticancer drugs on tumor growth and host body weight Thursday 15:15-16:40 |
IV-29 Melanie Titze A semi-mechanistic model to describe the bidirectional interaction between oncolytic reovirus and in vitro tumor growth of U87-glioblastoma cells Thursday 15:15-16:40 |
IV-42 Swantje Völler Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer: Results of the EPOC-MS-001 Study Thursday 15:15-16:40 |
IV-49 Wenyuan Xiong PK/PD modeling of the c-Met inhibitor MSC2156119J to establish the recommended Phase II dose Thursday 15:15-16:40 |
IV-51 Huixin Yu Integrated mechanism-based pharmacokinetic model for sunitinib and its active metabolite Thursday 15:15-16:40 |